Stocks perp · up to 50x · 10 venues

Novo Nordisk (NVO) stock perp

At 04:08 UTC on November 13, 2026, the Novo Nordisk (NVO) stock perp traded at $40.74 (-0.42% over 24 hours), with $4.2M in open interest across 10 venues, led by QFEX with 32%. Maximum leverage is 50x, on MEXC; open-interest-weighted funding is 0.0% annualized.

Get NVO Trade Alerts

Big position builds, funding swings and 10% days, by email. Unsubscribe in one click.

As of
  • Aster, 576 markets
  • QFEX, 237 markets
  • Variational, 588 markets
  • GRVT, 184 markets
  • Aevo, unavailable
  • OKX, 543 markets
  • Gate, 1082 markets
  • MEXC, 1188 markets
  • HTX, 412 markets
  • KuCoin, 721 markets
  • Binance, 758 markets
$40.74Live

Loading the price chart.

NVO at a glance

Open interest

Chart

$4.2M +2.0% 24h

VenueOpen interest24h change
QFEX$1.4M-0.1%
MEXC$1.1M+3.6%
Binance$953.9K
KuCoin$349.0K+1.3%

Volume, 24h

Chart

$1.0M -24.2% d/d

Volume / OI
0.24x
Nov 11, full day
$867.7K
  1. Nov 6: $1.5M
  2. Nov 7: $580.5K
  3. Nov 8: $583.3K
  4. Nov 9: $1.2M
  5. Nov 10: $1.1M
  6. Nov 11: $867.7K
Nov 6Daily volume, 6 daysNov 11

Funding

Chart

0.0% a year

Widest venue gap
0.0% long Aster, short QFEX
Paid over 24h, QFEX
0.000% longs paid

Liquidations

Chart

$868 24h

LongsShorts

WindowLongs liquidated against shorts liquidatedAmount
1hNone$0
4hNone$0
24h$868
7d–

Taker flow

Chart

57% buys, 24h

BuysSells

WindowTaker buys against taker sellsAmount
1hrecording
4hrecording
24hrecording
7drecording

Long vs short

No positioning data for this market.

Liquidity ±1%

Depth

$92.1K resting

BidsAsks

Bids / asks
$39.0K / $53.1K

Liquidations within 5%

No liquidation map for this market.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.